1. Home
  2. TEAD vs TNXP Comparison

TEAD vs TNXP Comparison

Compare TEAD & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TEAD
  • TNXP
  • Stock Information
  • Founded
  • TEAD 2006
  • TNXP 2007
  • Country
  • TEAD United States
  • TNXP United States
  • Employees
  • TEAD N/A
  • TNXP N/A
  • Industry
  • TEAD
  • TNXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • TEAD
  • TNXP Health Care
  • Exchange
  • TEAD NYSE
  • TNXP Nasdaq
  • Market Cap
  • TEAD 245.2M
  • TNXP 272.0M
  • IPO Year
  • TEAD N/A
  • TNXP N/A
  • Fundamental
  • Price
  • TEAD $2.38
  • TNXP $33.99
  • Analyst Decision
  • TEAD
  • TNXP Strong Buy
  • Analyst Count
  • TEAD 0
  • TNXP 2
  • Target Price
  • TEAD N/A
  • TNXP $585.00
  • AVG Volume (30 Days)
  • TEAD 404.3K
  • TNXP 777.9K
  • Earning Date
  • TEAD 08-16-2025
  • TNXP 08-15-2025
  • Dividend Yield
  • TEAD N/A
  • TNXP N/A
  • EPS Growth
  • TEAD N/A
  • TNXP N/A
  • EPS
  • TEAD N/A
  • TNXP N/A
  • Revenue
  • TEAD $959,268,000.00
  • TNXP $10,041,000.00
  • Revenue This Year
  • TEAD $65.64
  • TNXP $11.66
  • Revenue Next Year
  • TEAD $5.29
  • TNXP $793.18
  • P/E Ratio
  • TEAD N/A
  • TNXP N/A
  • Revenue Growth
  • TEAD 4.15
  • TNXP N/A
  • 52 Week Low
  • TEAD $2.34
  • TNXP $6.76
  • 52 Week High
  • TEAD $7.87
  • TNXP $130.00
  • Technical
  • Relative Strength Index (RSI)
  • TEAD N/A
  • TNXP 51.82
  • Support Level
  • TEAD N/A
  • TNXP $30.82
  • Resistance Level
  • TEAD N/A
  • TNXP $37.42
  • Average True Range (ATR)
  • TEAD 0.00
  • TNXP 3.21
  • MACD
  • TEAD 0.00
  • TNXP -1.01
  • Stochastic Oscillator
  • TEAD 0.00
  • TNXP 33.00

About TEAD TEADS HLDG CO

Teads Holding Co is the omnichannel outcomes platform for the open internet, driving full-funnel results for marketers across premium media. Its Focus on meaningful business outcomes for branding and performance objectives, the combined company ensures value is driven with every media dollar by leveraging predictive AI technology to connect quality media, beautiful brand creative, and context-driven addressability and measurement.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: